US Stock Market Move | SK Hynix (SKHY.US) rose by over 5% as Goldman Sachs Group, Inc. predicts a shareholder return rate of up to 8% by 2027.
On Thursday, SK Hynix (SKHY.US) rose by over 5%, reaching $164.77.
On Thursday, SK Hynix (SKHY.US) rose more than 5%, closing at $164.77. In news reports, SK Hynix officially announced its long-awaited shareholder return policy after the market closed on August 19, 2026 planning to repurchase and cancel shares worth 40 trillion won, involving 24.07 million shares (accounting for 3.3% of outstanding shares as of the end of Q2 2026), equivalent to approximately $28.9 billion. This scale not only represents the largest share buyback in the history of South Korean listed companies but also exceeds the approximately $26.5 billion raised by Hynix through ADR financing in early July this year.
Wall Street's two top institutions, JPMorgan Chase and Goldman Sachs Group, Inc., both gave a highly positive assessment of this announcement in their latest research reports on August 20. JPMorgan Chase noted that the shareholder return policy has been substantially upgraded from "not exceeding 50%" to "no less than 50%," indicating a shift from a policy ceiling to a policy floor. Goldman Sachs Group, Inc. predicts a shareholder return rate of up to 8% in 2027 and anticipates an additional buyback of about 7 trillion won in the future.
Related Articles

LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.

CHINA POWER (02380) achieved strong growth in its hydropower segment in the first half of the year, with clean energy installed capacity accounting for over 80%.

3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.
LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.

CHINA POWER (02380) achieved strong growth in its hydropower segment in the first half of the year, with clean energy installed capacity accounting for over 80%.

3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.

RECOMMEND





